Valeant Ex-CFO Schiller Named Interim CEO With Pearson Ill
- Ingram to become interim chairman during chief's medical leave
- Naming single CEO said to clarify management structure
Why Schiller as Interim CEO Is Good for Valeant
This article is for subscribers only.
Valeant Pharmaceuticals International Inc. named Howard Schiller to run the company as interim chief executive officer, tapping a board member and former top executive to help restore the company’s image while Michael Pearson remains hospitalized with severe pneumonia.
Bob Ingram, a board member and former Glaxo Wellcome CEO, will become interim chairman, also replacing Pearson, Valeant said in a statement. The timing of Pearson’s return from medical leave remains uncertain, said the drugmaker, which initially disclosed his hospitalization on Christmas Day.